|RedHill Biopharma Ltd -- USA Stock|| |
USD 0.97 0.00 0.00%
Chief Accounting Officer
Mr. Uri Hananel Aharon serves as Chief Accounting Officer at Redhill Biopharma Ltd, effective since 2012. His work experience includes the following roles Team Manager at Ernst Young Israel and Accounting Intern at Ziv Haft, BDO . He holds a Bachelors degree in Accounting and Economics from The Hebrew University of Jerusalem and a MBA degree, majoring in Business Taxation, from the College of Management Academic Studies, Rishon LeZion.
Age: 35 Executive Since 2011 MBA
972 3 541 3131 http://www.redhillbio.com
Aharon is a graduate of the Hebrew University and the Academic College for Management, Rishon Lezion .
The company has return on total asset (ROA)
of (29.24) %
which means that it has lost $29.24 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (21.0) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 969.85 K in total debt with debt to equity ratio (D/E) of 0.06 which may suggest the company is not taking enough advantage from borrowing. RedHill Biopharma Ltd has Current Ratio of 5.72 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
RedHill Biopharma Ltd., a biopharmaceutical company, primarily focuses on the development and commercialization of late clinicalstage, proprietary, orallyadministered, small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, and cancer. RedHill Biopharma Ltd (REDIF) is traded on OTC Market in USA. It is located in Tel Aviv, and employs 12 people.